A novel diagnostic method and therapeutic treatment of acute pulmonary inflammation
- 總結
- Researchersat OSU have discovered a novel antibody that could constitute a new therapeuticmethod to restrict the pathogenesis of ALI/ARDS. In a clinically relevantanimal model of ALI, a novel monoclonal antibody discovered by the researcherssignificantly inhibits neutrophil influx into alveolar space. Becauseneutrophil inflammation is central to development of ALI, this antibody mayprove to be the therapeutic agent that is greatly needed for ALI/ARDS patients.Moreover, this anitibody could be used as a novel diagnostic marker forALI/ARDS. This is critical because current diagnosis of ALI/ARDS is performedby the presence of non-cardiogenic pulmonary edema and respiratory failure,which are non-specific measures subject to inter-observer variability.
- 技術優勢
- · Enables earlydetection of ALI/ARDS· Novel treatmentmethod to reduce severity of ALI/ARDS
- 技術應用
- · Quantitativediagnostic tool for ALI/ARDS· Method oftreatment for ALI/ARDS· Treatment forother inflammatory diseases, especially lung
- 詳細技術說明
- None
- *Abstract
-
None
- *Background
- Acute lung injury (ALI) and its severe form, acute respiratorydisease syndrome (ARDS), are life-threatening diseases with a variety ofcauses, including sepsis, trauma, and pneumonia. ALI and ARDS are characterizedby pulmonary endothelial and epithelial injury, and loss of the alveolarcapillary barrier with an influx of inflammatory cells. The incidence isestimated at 1.5 to 75 cases per 100,000 individuals and affects approximately190,000 Americans annually, with mortality rates ranging from 25% to 40%. The current treatment approach to ALI/ARDSrelies on ventilator and cardiovascular support. However, In spite of thesetreatments, unacceptable morbidity and mortality remain in ALI/ARDS patients. Thereis a great need for novel pharmacological therapeutics that can help reduce themorbidity and permanent lung tissue damage associated with ALI/ARDS.
- *Stage of Development
- Proof of concept stage.
- 國家/地區
- 美國

欲了解更多信息,請點擊 這裡